The effects of cyclophosphamide and its uroprotective agents, mesna and hyperbaric oxygen, on urinary bladder motility in guinea pigs.
The aim of this research was to observe the effects of cyclophosphamide and its uroprotective agents, mesna and hyperbaric oxygen (HBO), on the motility of urinary bladder muscle in guinea pigs. In the experimental groups, mesna and cyclophosphamide were intraperitoneally injected at a dose of 21.5 mg/kg and 68.1 mg/kg, respectively. For the combination of mesna and cyclophosphamide, one dose of mesna was injected 20 min before cyclophosphamide administration and three additional injections of mesna were repeated every three hours. A total of 8 HBO exposures were performed at 2.8 ATA for 90 min twice daily for another experimental group. In the HBO and cyclophosphamide combined group 5 HBO exposures were given prophylactically before cyclophosphamide. The combination of mesna, HBO and cyclophosphamide was administered by the same procedure. The contractions obtained in response to acetylcholine (ACh, 10(-4) M) in the control group were reduced using cyclophosphamide and HBO individually, but not by mesna. However, the contractions belonging to the various combinations of these three agents were not different from those seen in the control group. On the other hand, the combinations of cyclophosphamide, mesna and HBO showed higher responses to ACh than the groups in which cyclophosphamide and HBO were used individually, while the responses elicited by the cyclophosphamide and HBO combination were greater than those seen in the group treated with HBO only.
Sağmanligil
V
V
Department of Physiology, Veterinary Faculty, Ankara University, Turkey. sagmanli@veterinary.ankara.edu.tr
Etlik
O
O
Pişkin
I
I
Tomur
A
A
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000494:pharmacology*; D006168:Guinea Pigs; D006931:Hyperbaric Oxygenation; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use*; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D001743:Urinary Bladder / Q000187:drug effects*
D018906:Antineoplastic Agents, Alkylating; D020011:Protective Agents; D003520:Cyclophosphamide; D015080:Mesna